Across its extensive product suite, clinical stage pharmaceutical development company Incannex Healthcare is developing a unique psilocybin therapy for the treatment of generalised anxiety disorder (GAD).
Clearmind Medicine Inc. announced it has entered into a Development and Supply agreement with Aragen Life Sciences Pvt. Ltd (Aragen) for the production of its innovative molecule, 5-Methoxy-2-aminoindane (MEAI).
Entheon Biomedical Corp., a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its operations and progress on its strategic initiatives.
Pasithea Therapeutics said its unit Pasithea Clinics administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression in the UK.
The CEO of Universal Ibogaine, Dr Rami Batal, shares the latest company happenings and what to expect from them in the future.
Silo Pharma has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain assets currently under development, including Alzheimer’s disease.
Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., is pleased to announce that it has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives such as DMT and psilocybin.
MYND Life Sciences has announced it has entered into an agreement to acquire the right, title and interest in and to the intellectual property rights for the use of psychedelics to treat Dementia from Cava Healthcare Inc.
Irwin Naturals has created a wholly-owned unit, Irwin Naturals Emergence, in preparation for its entry into the psychedelic mental health industry.
Delic Holding Corp Inc. announced that its subsidiary, Delic Labs, has entered into a co-marketing partnership with GT Research Inc., a leader in applying cutting edge computational and bio-technology to cannabis and psychedelics.